On June 19, 2024, David Lazar notified TRACON Pharmaceuticals, Inc. that he voluntarily resigned from his position as Chief Business Development Officer of the Company, effective June 19, 2024. Mr. Lazar?s resignation is not a result of any disagreement with the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6222 USD | -20.23% |
|
-18.66% | -82.23% |
07-02 | TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from S&P TMI Index | CI |
07-01 | TRACON Pharmaceuticals to Explore Strategic Alternatives Leveraging its In-House Product Development Platform | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.23% | 1.67M | |
+7.83% | 100B | |
+8.42% | 42.34B | |
-13.04% | 32.76B | |
+80.80% | 29.46B | |
-10.92% | 16.31B | |
+1.93% | 14.39B | |
-6.77% | 12.23B | |
+177.16% | 10.47B | |
+4.12% | 8.97B |
- Stock Market
- Equities
- TCON Stock
- News TRACON Pharmaceuticals, Inc.
- TRACON Pharmaceuticals, Inc. Announces Resignation of David Lazar as Chief Business Development Officer